Background and Purpose-Recent studies using cultured cells and rodent intracerebral hemorrhage (ICH) models have implicated RIPK1 (receptor interacting protein kinase-1) as a driver of programmed necrosis and secondary injury based on use of chemical inhibitors. However, these inhibitors have off-target effects and cannot be used alone to prove a role for RIPK1. The aim of the current study was to examine the effect of genetic inhibition of the kinase domain of RIPK1 in a mouse ICH model. Methods-We subjected 2 lines of mice with RIPK1 point mutations of the kinase domain (K45A and D138N), rendering them kinase inactive, to autologous blood ICH and measured acute cell death and functional outcome.
I
ntracerebral hemorrhage (ICH) accounts for 15% of strokes affecting 2 million people per year worldwide, with ≤70% mortality and <40% of survivors functioning independently at 3 months. 1 Clinical trials evaluating aggressive blood pressure management, decompressive craniectomy, stereotactic hematoma evacuation, and intraventricular thrombolysis failed to improve the neurological sequelae in ICH survivors. [2] [3] [4] [5] Thus, specific treatment to improve outcome after ICH remains elusive, in part because of incomplete understanding of secondary injury mechanisms. [6] [7] [8] The molecular biology of ICH-induced cell death has been a major focus of research efforts, with early studies emphasizing a role for caspase-mediated apoptosis. 9, 10 However, brain specimens from humans with ICH also exhibit necrosis, suggesting additional modes of neuronal death. 11, 12 Necroptosis is a form of necrosis mediated by the kinase domains of serine/ threonine RIPK-1 and -3 (receptor interacting protein kinase-1 and -3) which phosphorylate and activate MLKL (mixed lineage kinase domain-like) protein in a RIPK1/RIPK3/MLKL necrosome complex. 13, 14 RIPK1 kinase activity can also induce apoptosis via assembly of a RIPK1/FADD/RIPK3/ Caspase-8 ripoptosome 15, 16 and inflammation by RIPK3/ERK/ NFκB/cFos activation 17 or by activation of inflammasomes. 18 Thus, RIPK1 is a master regulator of necrosis, apoptosis, and inflammation. Studies using cultured neurons 19, 20 and astrocytes 21 show that blood derivatives can induce RIPK1 activation, necrosome assembly, and necrosis that is inhibitable by necrostatin-1, a pharmacological RIPK1 inhibitor-suggesting that brain cells may undergo necroptosis in response to ICH.
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Moreover, necrotic phenotypes occur in rodent collagenase and autologous blood ICH models, [22] [23] [24] [25] [26] and genetic deletion of RIPK3 inhibits plasmalemma permeability after collagenase ICH. 26 A growing number of studies have implicated RIPK1 and necroptosis in acute traumatic and ischemic brain injury, 13, 27, 28 as well as ICH, 19, 20, [22] [23] [24] [25] [26] based on protection with necrostatin-1. However, necrostatin-1 has off-target effects, 14 including inhibition of indoleamine-2,3-dioxygenase, and cannot be used alone to prove RIPK1 involvement in vivo. 29 This roadblock to understanding the role of RIPK1 in acute brain injury has persisted, until recently, in part because of lack of genetic tools to inhibit RIPK1.
Here, we used RIPK1 mutant mice with point mutations that render their kinase domain inactive (kinase dead), to interrogate RIPK1 kinase function in a mouse autologous blood ICH model. We also tested systemic administration of GSK′963, a potent and selective brain penetrant next-generation RIPK1 inhibitor. The results confirm a predominant role for RIPK1 as disease driver of ICH and validate future studies aimed at elucidating RIPK1 mechanisms in ICH, a devastating condition for which specific therapy is lacking.
Materials and Methods
All experimental protocols were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee and conducted according to the National Institutes of Health guide for the care and use of laboratory animals and Animal Research: Reporting of In Vivo Experiments guidelines. Studies were performed using adult (8-12 weeks, 25-30 g) male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME), RIPK1 K45A/K45A (RIP1 kinase-dead knock-in; a gift from GlaxoSmithKline, PA) 30 and RIPK1 D138N/D138N (RIP1 kinase-dead knock-in; a gift from Genentech, San Francisco, CA) 31 mouse lines derived solely from C57Bl/6. Mice were housed in a pathogen-free environment with 12-hour day/night cycles. Food and water were provided ad libitum. A descriptive table of experimental groups, the timeline of experimentation, and total number of mice is provided in Table I in the online-only Data Supplement. All experiments were performed in a fully randomized and blinded design.
Autologous Blood Injection ICH Model
Mice were anesthetized with isoflurane (2%) in 70% O 2 /30% N 2 O, and core temperature was maintained at 37°C±1°C with a heating pad. A midline scalp incision was made, and a 1-mm burr hole was drilled on the right side of the skull (from bregma: 0.1 mm posterior, 2.5 mm lateral). Nonheparinized autologous blood (30 μL) collected from the facial vein was pumped into the right striatum (3.5 mm deep) using a 26-gauge Hamilton syringe and syringe pump (Stoelting, Wood Dale, IL) over 1 minute. The syringe was left in place for 10 minutes then withdrawn. The burr hole was sealed with bone wax, and the scalp sutured closed. Mice were recovered at 37°C for 1 hour. In the sham ICH group, mice underwent the same surgical procedures but with 30 μL sterile saline infusion.
Preparation of Brain Tissue and Quantification of Propidium Iodide-Positive and Fluoro-Jade B-Positive Cells
Propidium iodide (PI, 100 μg in 400 μL sterile phosphate buffered saline; Sigma, St. Louis) was administered to mice, and PI + cells were quantitated in hemorrhagic brain as described previously. 26 For FluoroJade B (FJB) staining, brain sections were post-fixed in 4% paraformaldehyde and stained according to the manufacturer's instructions. FJB + cell counts were performed as described previously.
26
Immunohistochemistry HMGB1 (high mobility group box 1) and neuronal nuclei (NeuN) immunohistochemistry was performed as previously described.
Western Blotting
Mice were transcardially perfused with heparin containing saline, and brains were frozen on dry ice and kept at −80°C until use. Two-hundred micrometers coronal sections were cut on a cryostat and striatal hemorrhagic lesions were dissected along with similar amounts of contralateral striatum, and brain tissue was subjected to Western blot as previously described 32 using rabbit polyclonal HMGB1 antibody (1:2000, Abcam) and mouse monoclonal NeuN antibody (1:1000, Millipore) overnight at 4°C and horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG secondary antibodies (1:3000, Cell Signaling, Cambridge, MA) for 1 hour at room temperature. Protein bands were normalized to β-actin (1:3000, Cell Signaling), and densitometry was performed using National Institutes of Health Image J software. Cerebrospinal fluid samples were taken from the cisterna magna and blotted as previously described.
33
Grid Walk Test
The grid walk test was performed as previously described.
34
Morris Water Maze
The Morris water maze (MWM) was performed as previously described 32 with a total of 7 hidden platform trials and 90s maximum latency to the platform.
Statistical Analyses
Data are mean±SEM. PI + , FJB + , NeuN + , and Hoechst + cell counts, densitometry, and MWM probe trial data were analyzed by t test. MWM hidden and visible platform trials, and weight loss data, were analyzed by repeated measures ANOVA (group×time) using GraphPad Prism 7. Behavioral tests were powered based on our previous publications. All other tests were powered assuming 50% difference between group means and estimated SD 30% and power 0.8.
Results
Autologous Blood ICH Induces Plasmalemma Damage and Fatal Cellular Injury
PI labeling showed an increase in cells with plasmalemma damage beginning at 6 and peaking at 24 hours, with return to sham injury levels by 7 days in core and peripheral hemorrhagic regions ( Figure 1A We next sought to confirm these findings with GSK′963, a pharmacological RIPK1 inhibitor, 35 administered intraperitoneally (25 mg/kg) every 3 hours beginning at the time of ICH. Compared with vehicle, GSK′963 significantly reduced the numbers of FJB + cells in peripheral hemorrhage regions, whereas the reduction in the core failed to reach significance ( Figure 5 ). Of note, NeuN histochemistry did not prove feasible to assess neuronal cell numbers in the hemorrhagic lesion ( Figure III in the online- Figure 6B ). Figure 6C ) and in probe trials ( Figure IV in the online-only Data Supplement). After ICH, compared with WT, RIPK1 K45A/K45A and RIPK1 D138N/D138N performed significantly better on hidden platform trials with no differences in visible platform ( Figure 6D 
Discussion
Recent studies using in vitro and in vivo ICH models have suggested a role for RIPK1 as a disease driver based on studies with necrostatin-1 or siRNA-mediated RIPK1 knockdown. 20, [23] [24] [25] [26] [27] 29 To our knowledge, this is the first study to examine RIPK1 in any acute brain injury model using genetic tools. Mice with either of 2 distinct kinase-inactivating RIPK1 point mutations had significantly reduced cells with plasmalemma damage, reduced acute neuronal cell death, and improved physiological (weight loss/gain after injury) and functional (MWM) outcomes. In addition, systemic administration of the RIPK1 inhibitor GSK′963 also reduced neuronal death at 24 hours after ICH, similar to results in RIPK1 mutant mice. The data validate an important role for RIPK1 in the pathogenesis of cell death and functional outcome after ICH and support the idea that RIPK1 is a therapeutic target for patients with ICH. In vivo PI labeling detected cells with plasmalemma damage and presumed necrosis, or late apoptosis, as previously reported in a collagenase ICH model. 26 In that study, PI + cells peaked at 48 hours, whereas peak numbers appeared by 24 hours in our autologous blood ICH model. To confirm that PI labeling signals fatal cellular injury after ICH, we performed pulse labeling experiments showing rapid disappearance of PI + cells labeled at 24 or 48 hours after injury. The kinetics of PI + cell loss obtained herein are in striking contrast to the much slower disappearance of PI + cells from injured brain after controlled cortical impact. 36 The robust findings of nuclear translocation of HMGB1 is consistent with passive release from injured/necrotic cells, but is not specific for necrosis as HMGB1 may be actively released from stimulated inflammatory cells. 37 The findings that genetic or pharmacological RIPK1 inhibition reduced numbers of PI + and FJB + cells constitutes strong biochemical evidence of necroptosis, although RIPK1 can also promote apoptosis 38 which can present with plasmalemma damage at later stages. Taken together, the cellular and biochemical data do not discount the possibility of apoptotic death programs in PI + cells, but are consistent with the idea that necroptosis contributes to cell death after ICH, and that RIPK1 is an important driver of programmed neuronal death in this model. Further studies are needed to show inhibition of mechanisms specific for necroptosis in RIPK1 mutant mice, such as MLKL and RIPK3 phosphorylation events. 17, 31 Moreover, Hoechst + cell count data also support a protective role for RIPK1 inhibition as suggested by the increased numbers of Hoechst + cells remaining in the hemorrhagic lesion of RIPK1 D138N/D138N mice at 24 and 48 hours ( Figure Genetic inhibition of RIPK1 kinase activity also improved functional recovery and physiology after ICH, as evidenced by reduced overall weight loss in both RIPK1 mutants on the first postinjury day, and faster recovery to baseline weight versus WT. Interestingly, RIPK1 K45A/K45A mutants had an exaggerated response to sham ICH that resulted in a more pronounced weight loss and prolonged weight recovery versus WT. Despite these differences, injured RIPK1 K45A/ K45A mice had improved weight gain and performance in the water maze versus injured WT, suggesting a robust degree of protection by the RIPK1 K45A/K45A mutation in the context of ICH. Hidden platform performance in the MWM was also improved in injured RIPK1 D138N/D138N mutants versus WT. On the basis of the previous reports of marked phenotypic differences in various point mutant RIPK3 kinase-dead mice, 16 it is not surprising that RIPK1 K45A/K45A and RIPK1 D138N/D138N lines showed different phenotypes with sham injury in some of the outcome measures in the current study. These results may be because of slight genetic differences in background strains, but RIPK1 D138N/D138N and RIPK1 K45A/K45A are made in C57Bl/6 mice without DNA from other strains. 30, 39 More likely, the observed differences are because of differential effects of specific kinase domain mutations on RIPK1 function overall. The finding that hidden platform performance was not different between sham-injured and injured RIPK1 K45A/K45A and RIPK1 D138N/D138N mice, whereas WT ICH mice performed significantly worse than WT shams suggests that RIPK1 may be a therapeutic target to limit at least some functional deficits induced by ICH. Others have reported improved functional outcomes with intracerebroventricular administration of necrostatin-1, or siRNA against RIPK1, in rodent ICH models. [23] [24] [25] [26] [27] 29 Our data confirm and support the involvement of RIPK1 suggested by those previous studies, but not in all functional tests as no differences among groups were observed in the grid walk test.
RIPK1 could mediate cell death and functional outcome through several distinct mechanisms. The kinase activity of RIPK1 is required for necrosome assembly via phosphorylation and activation of RIPK3 and association with MLKL. Phosphorylation of MLKL in the necrosome induces its activation and translocation to the cell membrane, where it induces necroptosis in part by permeabilizing the plasmalemma via unknown mechanisms.
14 In addition to necrosis, RIPK1 can assemble a RIPK1/RIPK3/FADD/caspase-8 ripoptosome complex, which can induce apoptosis via activation of caspase-8, or inflammation via inflammasome activation. 14, 15, 18 Our group recently reported an additional pathway by which RIPK1 mediates inflammation, by activating a RIPK3/ERKI/II/cFos/NFκB pathway distinct from necroptosis. 17 The NFκB domain of RIPK1 is not inhibited by kinase domain mutations, so RIPK1 mutants used herein might still be expected to exert inflammatory activity after ICH. Future studies in our laboratory are aimed at elucidating specific mechanisms of RIPK1 in the pathogenesis of cellular injury and death (eg, apoptosis and necrosis) and inflammation after ICH.
Previous studies in mouse collagenase ICH models demonstrated that intracerebroventricular injection of necrostatin-1 before the development of hematoma improved several clinically relevant outcomes after ICH, including PI + cells, edema, blood-brain barrier disruption, inflammation, and neurological scores. [23] [24] [25] [26] [27] 29 These studies suggested a role for RIPK1, but the high local concentrations of necrostatin-1 infused in brain, and its known off-target effects, precluded these studies from proving a role for RIPK1 in vivo. We used systemic administration of GSK′963, a next-generation potent, selective small molecule RIPK1 inhibitor, 35 to complement the use of RIPK1 mutant mice. Systemic administration of GSK′963 reduced acute neuronal death at 24 hours, albeit not as robustly as seen in mutant mice. This result is expected because drug penetration to core hemorrhage regions may be inconsistent because of relative lack of blood flow, edema, or other reasons. GSK′963 inhibits RIPK1 in vitro 200-fold more potently than necrostatin-1 and inhibits endotoxin-induced hypothermia in mice to a greater extent also. 35 Human RIPK1 inhibitors are currently in clinical trials of inflammatory diseases of the skin, colon, and joints. Data from the current study suggest the development of RIPK1 inhibitors for humans with hemorrhagic stroke.
The current study builds on recent findings that necroptosis signaling intermediates are observed in brain after autologous blood ICH in rodents. Zille et al 19 (2017) recently showed that ERK phosphorylation, a key step in RIPK1 inflammatory signaling, 17 occurs after ICH in mice. Shen et al 20 (2017) showed that after autologous blood ICH in rats, the activated form of RIPK1 (phosphoserine RIPK1) was increased in hemorrhagic brain, as well as RIPK1/RIPK3/MLKL/caspase-8 interaction. Downregulation of RIPK1 by siRNA reduced necrosome assembly and PI + cells, blood-brain barrier permeability to Evans blue, and brain edema. Whether or not these findings are attributable to inhibition of the kinase domain of RIPK1, other RIPK1 molecular domains, or another molecule(s) remain to be determined because siRNA reduces total levels of RIPK1 protein and may have off-target effects on other RNA species. Nonetheless, the study by Shen et al 20 (2017) , along with our previous report showing reduced PI + cells after ICH in RIPK3 knockout mice, complements data from the current study that strongly argue for a role for RIPK1 and RIPK3 in the pathogenesis of ICH.
Summary/Conclusions
Genetic evidence presented herein confirms an important role for RIPK1 kinase activity as a disease driver in ICH. Future studies are needed to determine the exact mechanisms (necrosis, apoptosis, inflammation) responsible for improved outcomes with RIPK1 inhibition, and to identify additional RIPK1 signaling pathways that may serve as therapeutic targets for patients with ICH, for which no specific therapy is currently available to reduce neuronal cell death and improve outcome.
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